Caplacizumab is a humanised bivalent Nanobody that consists of two identical humanised building blocks (PMP12A2hum1), genetically linked by a three-alanine linker, targeting the A1-domain of von Willebrand factor and inhibiting the interaction between von Willebrand factor and platelets. As such, caplacizumab prevents the ultralarge von Willebrand factor-mediated platelet adhesion, which is characteristic of aTTP. It also affects the disposition of von Willebrand factor, leading to transient reductions of total von Willebrand factor antigen levels and to concomitant reduction of factor VIII:C levels during treatment.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B01AX07 | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AX Other antithrombotic agents | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| CABLIVI Powder and solvent for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Caplacizumab is an active ingredient of these brands:
United States (US)Austria (AT)Brazil (BR)Canada (CA)Croatia (HR)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Israel (IL)Japan (JP)Lithuania (LT)Netherlands (NL)Poland (PL)Romania (RO)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
